Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
NCT01239342 · National Cancer Institute (NCI) · PHASE2 · terminated · last registry update 2019-10-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AKT2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-10-06Also stopped (withdrawn): Icahn School of Medicine at Mount Sinai, Ipatasertib + Paclitaxel (NCT04561817)
- 2020-09-30Also stopped (terminated): ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), ARQ 092 + carboplatin + paclitaxel (Closed) + ARQ 092 + paclitaxel (Closed) (NCT02476955)
- 2020-09-24Also stopped (terminated): Prescient Therapeutics, Ltd., Triciribine + Carboplatin (NCT01690468)
- 2020-09-24Also stopped (terminated): Prescient Therapeutics, Ltd., Cyclophosphamide + Doxorubicin Hydrochloride (NCT01697293)
- 2020-07-30Phase 3 first posted: AstraZeneca, Capivasertib + Abiraterone Acetate (NCT04493853)
- 2020-03-12Phase 3 first posted: AstraZeneca, Fulvestrant + Capivasertib (NCT04305496)
- 2020-02-24Results posted on the registry: National Cancer Institute (NCI), Trametinib + Uprosertib (NCT01979523)
- 2019-12-05Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 + Bicalutamide (NCT01251861)
- 2019-11-26Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Ipatasertib (NCT04177108)
- 2019-11-12Results posted on the registry: Merck Sharp & Dohme LLC, MK-2206 + docetaxel (NCT00848718)
- 2019-07-09Results posted on the registry: Novartis Pharmaceuticals, GSK2110183 (afuresertib) (NCT01531894)
- 2019-06-25Phase 3 first posted: AstraZeneca, Capivasertib + Paclitaxel (NCT03997123)
- 2019-05-20Also stopped (terminated): Samsung Medical Center, AZD5363 + paclitaxel (NCT02449655)
- 2019-04-04Phase 3 first posted: Karolinska Institutet, Enzalutamide Oral Capsule + Abiraterone Oral Tablet (NCT03903835)
- 2019-04-01Results posted on the registry: Merck Sharp & Dohme LLC, MK-2206 (NCT00670488)
- 2018-10-31Results posted on the registry: Merck Sharp & Dohme LLC, MK-2206 + Trastuzumab (NCT00963547)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision